11 min read
Monthly FDA Guidance and Regulatory News Review - September 2026
This September 2026 regulatory update focuses on FDA’s new guidance on neonatal parenteral nutrition compounding and...
Meet Veristat at the 8th Annual Gene Therapy Development Summit
Advancing Gene Therapies for Patients with Rare Diseases and Limited Treatment Options.
Veristat is proud to participate in the 8th Annual Gene Therapy Development Summit, a premier event being held in Boston, MA, March 25-27, dedicated to transforming the future of gene therapies for rare and common diseases.
Your Gene Therapy Development Partner
At Veristat, we specialize in bringing revolutionary therapies to life. The knowledge we have amassed over 30 years has been game-changing for sponsors. From strategic planning and clinical trial execution to regulatory consulting, our creative approaches have helped them overcome daunting evidentiary and regulatory hurdles to gain swift and successful therapy approval. Tailored Strategies and Expert Insights
With 35% of our work supporting rare and ultra-rare diseases, Veristat brings unmatched experience to gene therapy programs. In the past five years, we’ve:
- Supported 350+ clinical trials and consulting projects for rare diseases
- Managed 40+ US and European regulatory marketing applications
- Celebrated the success of clients receiving 30 regulatory approvals for marketing applications prepared by Veristat teams
- Delivered customized solutions for regulatory strategies, patient recruitment, and trial execution
We ensure rare disease trials qualify for accelerated regulatory pathways, such as Orphan Drug Designation or Priority Review, and support your team through every milestone to bring therapies to patients faster.
Meet with Veristat:
Erin Gaffney - Senior Business Development Director
Schedule a meeting with Erin to discuss how Veristat can accelerate your gene therapy program.
Learn more about the conference
8 min read
Monthly FDA Guidance and Regulatory News Review - August 2026
Sep 21, 2026 Veristat Blog
This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...